Tags » Chronic Lymphocytic Leukemia

Juno Therapeutics and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies

SEATTLE & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Juno Therapeutics, Inc., a leading biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and Editas Medicine, a leader in genome editing, today announced an exclusive collaboration focused on creating chimeric antigen receptor (CAR T) and high-affinity T cell receptor (TCR) therapies to treat cancer. 843 more words

Acute Myeloid Leukemia

Novartis presents new data on 21 medicines and 11 investigational compounds at ASCO and EHA

Basel, May 27, 2015 – Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, and the Congress of the European Hematology Association (EHA), June 11-14. 1,264 more words

Preclinical & Clinical

AbbVie Announces Expiration of Hart-Scott-Rodino Waiting Period for AbbVie's Acquisition of Pharmacyclics

NORTH CHICAGO, Ill., May 22, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 for AbbVie’s purchase of Pharmacyclics, Inc. 744 more words

Multiple Myeloma

AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics

NORTH CHICAGO, Ill., May 21, 2015 /PRNewswire/ — AbbVie (NYSE: ABBV) announced today the per share offer consideration amounts pursuant to its previously announced offer to acquire each outstanding share of common stock of Pharmacyclics, Inc. 341 more words

Multiple Myeloma

Ofatumumab and Daratumumab Data to Be Presented at 20th Congress of EHA

Copenhagen, Denmark; May 21, 2015 – Genmab A/S (OMX: GEN) announced today that data on ofatumumab and daratumumab will be presented at the 20th Congress of the European Hematology Association (EHA) in Vienna, June 11-14.  1,655 more words

Preclinical & Clinical

New Patent Issued for Eagle Pharmaceuticals’ Bendamustine Rapid Infusion Product

WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) (“Eagle” or the “Company”) today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. 377 more words

Chronic Lymphocytic Leukemia

Kite Pharma Reports First Quarter 2015 Financial Results

SANTA MONICA, Calif., May 15, 2015 (GLOBE NEWSWIRE) — Kite Pharma, Inc. (Kite) (Nasdaq:KITE), a clinical-stage biopharmaceutical company focused on developing engineered autologous T cell therapy (eACT™) products for the treatment of cancer, today reported financial results for the quarter ended March 31, 2015. 918 more words

Preclinical & Clinical